Tag Archives: Chris Shibutani

Alkermes (ALKS) Gets a Buy Rating from Cowen & Co.

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $34. The company’s shares closed last Monday at $22.62, close to its 52-week low

Cowen & Co. Keeps Their Hold Rating on Puma Biotechnology (PBYI)

In a report released today, Chris Shibutani from Cowen & Co. maintained a Hold rating on Puma Biotechnology (PBYI – Research Report), with a price target of $25. The company’s shares opened today at $11.13, close to its 52-week low

Cowen & Co. Sticks to Their Buy Rating for G1 Therapeutics Inc (GTHX)

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on G1 Therapeutics Inc (GTHX – Research Report). The company’s shares closed yesterday at $23.48. According to TipRanks.com, Shibutani is a 4-star analyst with an

Syndax Pharmaceuticals Inc (SNDX) Gets a Buy Rating from Cowen & Co.

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Syndax Pharmaceuticals Inc (SNDX – Research Report). The company’s shares closed yesterday at $9.51, close to its 52-week high of $10.17. According to TipRanks.com,

Radius Health (RDUS) Gets a Hold Rating from Cowen & Co.

In a report released today, Chris Shibutani from Cowen & Co. maintained a Hold rating on Radius Health (RDUS – Research Report). The company’s shares closed yesterday at $23.23. According to TipRanks.com, Shibutani is a 4-star analyst with an average

Mirati Therapeutics (MRTX) Gets a Buy Rating from Cowen & Co.

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Mirati Therapeutics (MRTX – Research Report) yesterday. The company’s shares closed yesterday at $93.65. According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 5.2% and